Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: A case report

Journal of Clinical Pharmacy and Therapeutics

Volumn 31, Issue 4, 2006, Pages 389-392

  Lannoy, D ^a   Decaudin, B ^a   Grozieux De Laguerenne A ^a   Barrier, F ^a   Pignon, J M ^a   Wetterwald, M ^a   Odou, P ^b,c  

^a General Hospital Dunkerque   (France)

^b Faculty of Pharmaceutical and Biological Sciences   (France)

^c CENTRE HOSPITALIER   (France)

Author keywords

Defibrotide; Gemtuzumab; Sinusoidal obstructive syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; CYTARABINE; DAUNORUBICIN; DEFIBROTIDE; GAMMA GLUTAMYLTRANSFERASE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IDARUBICIN;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CASE REPORT; CHOLESTASIS; CLINICAL FEATURE; CLINICAL OBSERVATION; CYTOLYSIS; DEATH; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERAL CONDITION IMPROVEMENT; HEPATOMEGALY; HUMAN; LIVER SINUSOID; LOW DRUG DOSE; MALE; MONOTHERAPY; MULTIPLE ORGAN FAILURE; THROMBOCYTOPENIA; WEIGHT GAIN;

AGED; FATAL OUTCOME; FIBRINOLYTIC AGENTS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LEUKEMIA, MYELOID; MALE; POLYDEOXYRIBONUCLEOTIDES; SUCCINATES;

EID: 33745932473     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2006.00742.x     Document Type: Article

References (19)

1. Sievers EL, Larson RA, Stadtmauer EA et al. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD-33 positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19, 3244-3254.
2. Tsimberidou AM, Giles FJ, O'Brien S, Keating MJ, Kantarjian HM (2005) The role of gemtuzumab ozogamicin in acute leukaemia therapy. British Journal of Haematology, 132, 389-409.
3. Zein N, Sinha AM, McGahren WJ, Ellestad GA (1988) Calicheamicin gamma 1: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science, 240, 1198-1201.
4. Amadori S, Suciu S, Willemze R et al. (2004) Sequential administration of gemtuzumab ozogamicine and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica, 89, 950-956.
5. Giles FJ, Kantarjian HM, Kornblau SM et al. (2001) Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer, 92, 406-413.
6. Rajvanshi P, Shulman HM, Sievers EL, Mc Donald GB (2002) Hepatic sinusoidal obstruction after gemltuzumab ozogamicin (Mylotarg) therapy. Blood, 99, 2310-2314 Erratum in: Blood, 99, 3915.
7. DeLeve LD, Shulman HM, McDonald GB (2002) Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Seminar Liver Disease, 22, 27-42.
8. Wadleigh M, Richardson PG, Zahrieh D et al. (2003) Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 102, 578-582.
9. Neumeister P, Eibl M, Zinke-Cerwenka W, Scarpatetti M, Sill H, Linkesch W (2001) Hepatic venoocclusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate. Annals of Hematology, 80, 119-120.
10. Saviola A, Luppi M, Potenza L et al. (2003) Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide. British Journal of Haematology, 123, 752-753.
11. Bross P, Beitz J, Chen G et al. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research, 7, 1490-1496.
12. Coppell JA, Brown SA, Perry DJ (2003) Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Review, 17, 63-70.
13. McDonald GB, Hinds MS, Fischer LD et al. (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Annals of Internal Medicine, 118, 255-267.
14. Bastie JN, Suzan F, Garcia I et al (2002) Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin). British Journal of Haematology, 116, 924.
15. Falanga A, Vignoli A, Marchetti M, Barbui T (2003) Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia, 17, 1636-1642.
16. Violi F, Ferro D, Saliola M, Quintarelli C, Basili S, Balsano F (1992) Effect of oral defibrotide on tissue-plasminogen activator inhibitor balance. European Journal of Clinical Pharmacology, 42, 379-383.
17. Chopra R, Eaton JD, Grassi A et al (2000) Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. British Journal of Haematology, 111, 1122-1129.
18. Richardson PG, Murakami C, Jin Z et al. (2002) Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood, 100, 4337-4343.
19. Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N (2004) Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood, 103, 1968.